Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $7.15 down -1.65% from its previous closing price of $7.27. In other words, the price has decreased by -$1.65 from its previous closing price. On the day, 1.45 million shares were traded. TRVI stock price reached its highest trading level at $7.35 during the session, while it also had its lowest trading level at $7.03.
Ratios:
For a deeper understanding of Trevi Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.42 and its Current Ratio is at 22.42. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on August 21, 2025, initiated with a Overweight rating and assigned the stock a target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
On May 28, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $21.H.C. Wainwright initiated its Buy rating on May 28, 2025, with a $21 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 27 ’25 when Delfini Lisa bought 312,855 shares for $8.09 per share.
SCIASCIA THOMAS sold 2,631 shares of TRVI for $17,365 on Mar 25 ’25. The Chief Scientific Officer now owns 221,373 shares after completing the transaction at $6.60 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the President & CEO of the company, sold 5,263 shares for $6.58 each. As a result, the insider received 34,625 and left with 213,313 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 886557120 and an Enterprise Value of 667710528.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.72, which has changed by 1.3064516 over the last 52 weeks, in comparison to a change of 0.1716845 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $8.78, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is 2.50%, while the 200-Day Moving Average is calculated to be 29.79%.
Shares Statistics:
For the past three months, TRVI has traded an average of 2.02M shares per day and 2602890 over the past ten days. A total of 121.78M shares are outstanding, with a floating share count of 80.73M. Insiders hold about 33.70% of the company’s shares, while institutions hold 60.31% stake in the company. Shares short for TRVI as of 1755216000 were 10111945 with a Short Ratio of 5.01, compared to 1752537600 on 9951259. Therefore, it implies a Short% of Shares Outstanding of 10111945 and a Short% of Float of 9.62.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Trevi Therapeutics Inc (TRVI).The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.38 and -$0.44 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.49, with 8.0 analysts recommending between -$0.24 and -$0.65.
